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Abstract
Objective: To describe the features of HIV-associated chronic lung disease (CLD) in older children and 
adolescents living with HIV and to examine the clinical factors associated with CLD. This is a post-hoc 
analysis of baseline data from the BREATHE clinical trial (ClinicalTrials.gov, NCT02426112).
Methods: Children and adolescents aged 6-19 years were screened for CLD (defined as a FEV1 z-score <-1 
with no reversibility post-bronchodilation with salbutamol) at two HIV clinics in Harare, Zimbabwe and 
Blantyre, Malawi. Eligible participants with CLD (cases) were enrolled, together with a control group 
without CLD (frequency-matched by age group and duration on ART) in a 4:1 allocation ratio. A clinical 
history and examination was undertaken. The association between CLD and a priori-defined demographic 
and clinical covariates was investigated using multivariable logistic regression.
Results: Of the 1,585 participants screened, 419 (32%) had a FEV1 z- score <-1, of whom 347 were enrolled 
as cases (median age 15.3 years [IQR 12.7 -17.7]; 48.9% female), and 74 with FEV1 z-score>0 as controls 
(median age 15.6 years [IQR 12.1 -18.2]; 62.2% female). Amongst cases, current respiratory symptoms 
including cough and shortness of breath were reported infrequently (9.3% and 1.8%, respectively). 
However, 152 (43.8%) of cases had a respiratory rate above the 90th centile for their age. Wasting and 
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taking second-line antiretroviral treatment (ART) were independently associated with CLD.
Conclusions: The presence of CLD indicates the need to address additional treatment support for youth 
living with HIV, alongside ART provision, to ensure a healthier adulthood.
Keywords: HIV, Adolescents, Chronic Lung Disease, Africa
Introduction
In 2017, an estimated three million children and adolescents were living with HIV worldwide, 90% in Sub-
Saharan Africa (1). The incidence of HIV infection acquired through mother-to-child transmission has 
declined dramatically in recent years due to the scale-up of prevention of mother-to-child HIV 
transmission programmes as one component of global efforts to eliminate HIV (2,3). At the same time, 
however, increasing numbers of African children who were perinatally-infected with HIV during peak 
years of 1995 to 2002 are now reaching adolescence and adulthood, having been diagnosed and treated 
by national HIV programmes (4). As this large paediatric antiretroviral therapy (ART) clinic cohort reaches 
adulthood, common comorbidities that result from growing up with perinatally acquired HIV differ from 
comorbidities seen in adults living with behaviourally acquired HIV. The clinical outcomes for adolescents 
living with HIV since birth are becoming better described: these include growth failure, cardiac and 
neurological conditions and notably chronic lung disease (CLD) (5,6).  
The main focus of paediatric HIV programmes has been on strengthening the HIV care cascade: 
ensuring early HIV diagnosis, prompt ART initiation, and retention in care with sustained viral load 
suppression with relatively little attention paid to defining, diagnosing and managing novel co-morbidities 
(7,8).
Several studies in sub-Saharan Africa have reported high prevalence of chronic respiratory symptoms 
among older children and adolescents living with HIV, including both those with delayed HIV diagnosis 
and treatment, and those already established on ART (9–12). Prevalence can be as high as 25% to 37.5%, 
with the typical clinical picture being a history of chronic cough with reduced exercise tolerance, and an 
obstructive defect on spirometry with no response to bronchodilators (9–12). High resolution computed 
tomography (HRCT) suggests constrictive obliterative bronchiolitis (COB) with or without accompanying 
bronchiectasis as the underlying cause in most cases (referred to hereafter as presumptive HIV-related 
COB: PH-COB) (13). Chest radiographic findings are subtle and patients look well at rest, meaning that PH-
COB goes undiagnosed in busy African HIV clinics. 
The pathogenesis of PH-COB is poorly defined, with no histopathological studies to date, but we and 
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immune activation and dysregulated inflammation are the most likely cause (14). We are evaluating the 
potential role of azithromycin, which has antibacterial and immunomodulatory properties and 
effectiveness in bronchiectasis and cystic fibrosis (15,16), using a multi-site, individually randomised, 
double-blinded, placebo-controlled trial of weekly azithromycin for 48 weeks in children and adolescents 
meeting case-definitions for chronic lung disease: the BREATHE trial (17). 
The main aim of the (post-hoc) analysis presented here as a case-control study was to use baseline 
data from trial participants and controls to investigate potential risk-factors for CLD and to describe the 
clinical features.
Methods
Study Setting and Population
From June 2016 until August 2018, children and adolescents meeting definitions of perinatal HIV infection 
(defined as self-report of no sexual debut or blood transfusions, a history of orphanhood due to maternal 
HIV disease and/or of a sibling death due to HIV, guardian report as perinatal acquisition being the known 
mode of acquisition and characteristic clinical features (≥1 of stunting, history of recurrent minor 
infections (skin, upper respiratory tract) in childhood, and/or planar warts) were recruited from HIV clinics 
at Harare Children’s Hospital, Harare, Zimbabwe and the Queen Elizabeth Central Hospital, Blantyre, 
Malawi, using a multistep screening procedure, as detailed in the published protocol [clinicaltrials.gov 
NCT02426112](17). 
Case selection: HIV clinic attendees aged (6-19 years old), taking ART for 6 months, and z-score of 
below -1 for Forced Expiratory Volume at one second (FEV1), with no reversibility met our case definition 
of chronic lung disease (12,18). Forced Expiratory Volume at one second (FEV1) z-score <-1 with no 
reversibility was the case definition of CLD in the trial. This definition was chosen as the most objective 
definition for lung disease; FEV1 z-score has been shown to be strongly correlated with the most common 
abnormalities observed in high resolution computed tomography, and we anticipate that the 
effectiveness of azithromycin would be limited in those with advanced disease.  
Control selection: HIV clinic attendees with FEV1 z-score > 0 and no chronic cough in the past 3 
months were enrolled as controls, using frequency-matching for age (6-12 years and 13-19 years) and 
duration on ART (6 months to <2 years and 2 or more years). 
Study procedures
A standardized questionnaire was administered to participants and their guardians. Height and weight, 
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pulse oximetry (OxyWatch, Beiijing Choice Electronic Technology Co. Ltd).
Spirometry adhered to American Thoracic Society (ATS) standards, and used EasyOne World 
spirometers (ndd Medical Technologies, Inc., Andover, Massachusetts, USA). Spirometric indices were 
expressed as z-scores using GLI2012 reference ranges (19). Participants with a FEV1 z- score below -1 
underwent repeat spirometry 15 minutes after administration of 200µcg inhaled salbutamol via spacer. A 
high-quality spirometry trace was selected for each participant and the best test performed was defined 
as the largest sum of FEV1 and FVC.
An incremental shuttle walk test (ISWT) was performed to measure cardiorespiratory fitness in all 
cases (20,21). Cases did not undergo shuttle walk test if, at rest, SpO2 was less than 88%, heart rate was 
more than 120 beats/min and respiratory rate was more than 30 breaths/min or the participant had a 
physical impediment to optimal exercise e.g. a physical disability.
All participants were tested for tuberculosis with a sputum sample for Xpert™ MTB/RIF (Cepheid, 
Sunnyvale, CA, USA). CD4 count measurements used PIMA™ Analyser (Alere, Orlando, FL, USA) and HIV 
viral load used Xpert™ HIV-1 Viral Load (Cepheid, Sunnyvale, CA, USA), lower limit of detection 40 
copies/ml . 
Data Management and Analysis
Electronic data capture used clinical record forms (Google Nexus™ tablets, Google, Mountain View, CA, 
USA) and OpenDataKit software, uploaded, into Microsoft Access databases (Microsoft, Redmond, WA, 
USA). Analysis used Stata version 15.0 (StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC) 
Z-scores for height-for-age and weight-for-age used 1990 British growth reference curves (22). Heart 
rates and respiratory rates were compared to age-specific centiles developed by O’Leary et al (23).
Comparison between groups used t-test or Mann–Whitney U test for continuous data, and chi-
squared test for categorical data. Complete case multivariable logistic regression adjusting for matching 
variables age, duration of ART, and for other clinically important variables site, sex, weight-for-age, 
height-for-age, viral suppression, CD4 cell count, history of TB and ART regimen was used to investigate 
risk factors for CLD. BMI was co-linear with weight-for-age and height-for-age so was not included in the 
adjusted model. 
Ethical Considerations
Written informed consent was obtained from participants aged 18 years and from caregivers of younger 
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Medical Research Council of Zimbabwe, the Harare Hospital Ethics Committee, the Biomedical Research 
and Training Institute Institutional Review Board, Malawi-Liverpool Wellcome Trust Clinical Research Unit 
in Malawi, the London School of Hygiene and Tropical Medicine Ethics Committee and Regional 
Committee for Medical and Health Research Ethics in Norway.
Results
During the study period, 1,585 children and adolescents aged 6-19 years, taking ART for more than six 
months, attending for HIV care and residing within the study catchment area were sequentially screened 
(Figure 1). Spirometry was performed 1,603 times with 1,305 (81.4%) providing a spirometric trace of high 
quality. Overall, 419 (32.0%) participants had a FEV1 z-score <-1 with no reversibility post-
bronchodilatation, i.e. meeting the trial definition for CLD. Of these eligible participants, 347 (82.8%) were 
analysed for the main trial (“CLD group”, or cases in this paper) (Figure 1). The median age was 15.3 years 
[IQR 12.7-17.7] and 48.9% were female. A further 74 eligible participants with FEV1 z-score >0 were 
analysed for the control group, frequency matched by age and duration on ART (median age 15.6 years 
[IQR 12.1-18.2]; 62.2% female). The median FEV1 z-score was -1.91 [IQR -2.43 - -1.43] for the cases and 
0.52 [IQR 0.24-0.79] for the controls (Table 1).
Among the cases, current respiratory symptoms including cough and shortness of breath were 
reported infrequently (9.0% and 1.7%, respectively). At rest, however, 152 (43.8%) had a respiratory rate 
and 14 (4.0%) had oxygen saturation below 90%. The mean duration of shuttle walk was 10 minutes 38 
seconds (SD 2:00) with the mean difference in heart rate one-minute post shuttle walk in comparison to 
resting heart rate being 30.3 beats (SD 17.0 ) (Table 1). Thirteen cases did not undertake shuttle walk due 
to clinical findings. Hospital admissions in the previous year for chest-related problems were infrequent in 
both groups. 
A greater proportion of cases were taking second-line ART than controls (25.6% vs. 11.0%, p-
value=0.005) implying previous treatment failure. Similarly, 44.1% of cases had detectable viral load 
(>1000 copies/ml) at the time of enrolment, vs. 34.3% of controls. 27% of cases had a viral load <40 
copies/ml vs. 36% of controls.  The majority of both cases and controls were receiving cotrimoxazole 
prophylaxis, which is standard of care for children and adolescents in this setting regardless of CD4 count.
Over half (61.1%) of cases were stunted or underweight compared to 32.4% of controls. The 
prevalence of stunting, underweight and low BMI was higher in cases than controls (Table 1, p=0.001). 
Overall, 97 (28.0%) cases reported having received treatment for TB in the past at least once, vs. 9 (12.2%) 
controls (p=0.002).
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history of TB and receiving a second-line ART regimen (Table 2). There was no evidence of an association 
of CLD with CD4 count or HIV viral load. In the multivariable logistic regression there was strong evidence 
of an association between being a case and being underweight and weaker evidence that being a case 
was associated with a past history of TB and with being on second-line ART (Table 2). 
Discussion
This study highlights the substantial burden of CLD among treatment-experienced children and 
adolescents living with perinatally acquired HIV. Over one-third of participants who had a high-quality 
spirometry performed had an FEV1 z-score below -1 with no reversibility with bronchodilation. The 
median FEV1 z-score among the CLD group (-1.91) demonstrates the presence of obstructive disease. 
Symptoms such as cough and breathlessness were infrequently reported. The chronicity of the symptoms 
may lead to individuals “normalising” symptoms particularly in the context of perinatally-acquired HIV 
infection, where respiratory tract infections are common. However, almost half of cases had a high 
respiratory rate (above the 90th centile for age), implying significant respiratory compromise, despite 
exclusion of individuals with acute respiratory illness and those with active tuberculosis. These findings 
are consistent with studies reporting a high prevalence of CLD among children attending HIV care in Sub-
Saharan Africa (12,24–27).
In the pre-ART era, the most common cause of CLD in children was lymphoid interstitial pneumonitis 
(LIP), a lymphoproliferative disorder associated with interstitial accumulation of lymphocytes and plasma 
cells. The condition responds to ART and the incidence has declined and is seldom reported in the ART era 
(28,29). The typical findings of LIP on HRCT are ground-glass shadowing, nodules and cysts. In recent HRCT 
studies of children taking ART, the most common pattern was suggestive of constrictive obliterative 
bronchiolitis with LIP being an exceptional finding (13). 
A higher proportion of cases had an unsuppressed HIV viral load (>1000 copies/ml) than the control 
group, but this was not associated with low FEV1 z-score. It is important to note that the HIV viral load 
measurement was done at enrolment and is not a marker of long-term virological control; given that one-
quarter of cases are taking second-line therapy it is probable they have had a period of viremia  post 
initial  ART regimen. A key finding, however, was that a higher proportion of the cases were on second-
line ART (i.e. taking a protease inhibitor-based regimen) than the controls. This is an indication of poorer 
HIV virological control in the past, possibly caused by suboptimal adherence. It is recognised that HIV 
infection not only causes immunosuppression resulting in an increased risk of infections, but also 
promotes dysregulated systemic immune activation and inflammation, which has been implicated in the 
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Therefore, HIV viral replication and poor virological control may promote the development and/or 
progression of CLD. 
Notably, despite the controls being matched for age and duration of ART, cases had a significantly 
higher prevalence of wasting, stunting and a lower BMI than controls, which are also consequences of 
poorly controlled HIV infection (5,32). We have recently shown high levels of  cytomegalovirus (CMV) 
viraemia in children and adolescents taking ART, and that viraemia was associated with stunting as well as 
a low FVC z-score (33). CMV infection is a well-recognised co-factor for HIV disease progression and 
promotes immune activation, and may play a role in pathogenesis of CLD (34). 
A significantly higher proportion of cases than controls had been treated for tuberculosis in the past. 
There may be two explanations – post-tuberculosis sequelae may be contributing to CLD, but equally 
clinicians may be more likely to initiate HIV-positive children with CLD on anti-tuberculosis treatment due 
to their clinical presentation and the high risk of tuberculosis among individuals living with HIV in this 
setting. Post-tuberculosis lung disease can involve airflow obstruction and/or restrictive ventilatory 
defects, as well as impairment in gas exchange (35–38). Airflow obstruction is associated with decreased 
capacity to completely expel air out of the lungs and is probably due to inflammation-induced narrowing 
of airways (38). Studies in Asia and Africa have consistently reported an association between past 
pulmonary tuberculosis and decreased FEV1 or chronic obstructive airway disease among adults (39,40). 
In addition FVC may be affected by pulmonary tuberculosis through lung tissue scarring, bronchial 
stenosis, bronchiectasis, fibrosis and pleural changes (38,41). 
The strengths of this study were that individuals were screened sequentially and an objective case 
definition was used to recruit participants. Those with acute respiratory illness were excluded and all 
participants underwent screening for tuberculosis, so the findings are unlikely to be explained by acute 
infection. Spirometry was performed according to ATS standards and only those with high-quality tracings 
were enrolled into the study. Limitations of this study include its cross-sectional nature and therefore 
reverse causality cannot be excluded. The history of TB was obtained by self-report with no 
microbiological confirmation, and it is possible that those with CLD may have been over-treated for TB in 
the absence of an alternative diagnosis. In addition, although we postulate that PH-COB is the clinical 
diagnosis of the cases in this study with CLD, no imaging was performed to confirm this. However, our 
group has previously performed imaging studies, supporting the finding that adolescents living with 
perinatally acquired HIV, having a decreased FEV1 z-score have demonstrated radiological appearance of 
COB on high resolution CT imaging (13). The possibility of residual confounding by other factors such as 
socioeconomic factors, household smoking and exposure to indoor smoke cannot be excluded. However, 
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that these would explain the differences observed.
To date, HIV programmes have focused on achieving viral suppression and there has been much less 
emphasis paid to addressing the long-term consequences of HIV infection. The median age of ART 
initiation in the current cohort of adolescents in Africa is 8 years (compared to under one year in US 
cohorts), and the long period of untreated HIV infection may explain the high prevalence of CLD and other 
chronic comorbidities such as stunting observed in African children (42). Furthermore, adolescence is a 
particularly high-risk period for poor treatment adherence and rates of viral non-suppression and 
subsequent virological failure are much higher in adolescents compared to in younger children and adults 
(43,44). This study highlights the urgent need to focus on addressing chronic comorbidities  in addition to 
provision of ART alongside ensuring sustained viral suppression. 
The pathogenesis and natural history of CLD in children is not clear, and longitudinal studies are 
needed. Several questions remain in addressing CLD in children and adolescents growing up with HIV 
infection, including the optimum modality and frequency of screening for CLD in low-income settings. 
Symptoms screening and plain chest radiography are insensitive tools for detecting small airways disease 
(12). Studies to identify effective therapeutic modalities to prevent the decline of or improve lung 
function e.g. pulmonary rehabilitation warrant investigation to enable optimal health outcomes for 
children growing up with HIV.  
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Figure 1. Flow Chart for Eligibility
Individuals assessed for eligibility on non-clinical criteria (n= 1,585)
   Individuals rescreened after protocol v2.1 (n= 63)
Excluded (n= 45)
   Not a perinatal HIV infection (n= 8)
   Medical contraindication1 (n= 26 )
   Other reasons2 (n= 11 )
Enrolled into trial and randomised (n= 347)
FEV1 z-score low 4 (n= 447) 
   Reversible (n=  28)
   Eligible to continue screening (n= 419 )
Enrolled into comparison group (n= 74)
FEV1 z-score not low 5 (>0)
   Assessed for frequency match (n= 171)
Enrolment
Spirometry attempted (n= 1,603 times)
Excluded (n= 985)
   Unable to perform spirometry (n=  297)
   FEV1 z-score out of eligible ranges3 
(n= 688)
Excluded (n= 72)
   Declined further testing (n= 10)
   Medical contraindication6 (n=  
62)
Excluded (n= 97)
   Not a frequency match (n=  93)
   Excluded those identified during 
data cleaning with FEV1 z-
score<0 (n=  4)
Included in complete case analysis (n=323)
   Excluded from complete case analysis due 
to missing values (n=24)
    Included in complete case analysis (n=70)
 Excluded from complete case analysis 
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Notes
1. Medical contraindications were: taking a course of Digoxin, taking a prolonged course (>2 weeks) of 
fluconazole, past allergic reaction, history of jaundice or liver problems with past use of azithromycin, has 
worsening cough, breathlessness or sputum in the past 7 days, taking TB treatment
2. Other reasons were out of age range, pregnancy, on ART for <6 months, or no firm home address
3. A buffer zone was allowed between those with low FEV1 z-score and those to be recruited into the 
comparison group. 
4. Protocol v1 dated 15th Dec 2015   FEV1 z-score<-1.64, Protocol v2.1 dated 9th May 2017 in Zimbabwe 
and 1st June 2017 in Malawi, FEV1 z-score<-1
5. Enrolment of comparison cohort commenced after protocol v2.1 dated 9th May 2017 in Zimbabwe and 
1st June 2017 in Malawi
6. Medical contraindications were: Prolonged QTc interval, Unable to produce sputum to discount TB, 
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Table 1. Participant characteristics by FEV1 z-score
Characteristics CLD-group 
n=347











    0.85















Attending school currently, n (%)2 284 (83.0%) 65 (87.8%) 0.35
Same age as most children in class, n (%)3 182 (91.5%) 47 (95.9%) 0.52
Repeated ≥1 school grade, n (%)2 197 (58.3%) 28 (37.8%) 0.006
HIV and ART 
Years since HIV diagnosis, median (IQR) 7.4 (IQR 4.9, 9.7) 8.4 (IQR 4.7, 10.0) 0.33
Age at diagnosis (years), median (IQR) 7.6 (IQR 4.2, 10.5) 7.3 (IQR 4.1, 9.9) 0.41
Duration on ART (years), median (IQR) 6.3 (IQR 3.9, 8.5) 6.8 (IQR 3.9, 8.9) 0.48
Duration on ART2
>6 months to <2 years
2 to <4 years
4 to <6 years










Age at ART initiation (years), median (IQR) 8.4 (IQR 5.7, 11.6) 8.4 (5.1, 10.4) 0.39
Taking cotrimoxazole prophylaxis, n (%)2 313 (90.7%) 60 (84.5%) 0.04








HIV VL >1000 copies/ml, n (%) 152 (44.1%) 25 (34.3%) 0.12
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CD4 count < 200cells/mm3, n(%) 34 (9.9%) 6 (8.2%) 0.67
Anthropometric 
Weight-for-age z-score, mean (SD) -2.15 (1.47) -1.09 (1.24) <0.001
Underweight (weight- for-age z-score <-2), 
n (%)
181 (52.2%) 14 (18.9%) <0.001
Height-for-age z-score, mean (SD) -2.09 (1.22) -1.50 (1.00) <0.001
Stunted (height-for-age z-score <-2), n (%) 172 (50.4%) 22 (29.7%) 0.001
BMI-for-age z-score, mean (SD) -1.09 (SD 1.17) -0.21 (SD 1.05) <0.001
Low BMI (BMI-for-age z-score <-2), n (%) 69 (20.0%) 3 (4.1%) 0.001
Respiratory 
Past history of TB, n (%)2 97 (28.0%) 9 (12.2%) 0.002
Number of times previously treated for TB, 
range
1 to 3 1 to 2
-
Admitted for chest problems in the past 
one year, n (%)
6 (1.7%) 1 (1.4%) 0.82
Number of times admitted to hospital for 
chest problems, range
1 to 1 1 to 1
FEV1 z-score, median (IQR) -1.91 (IQR -2.43, 
-1.41)
0.52 (0.24, 0.79) <0.001
1 p-values for proportions are chi-squared, for medians are Wilcoxon rank sum, and for means are t-test 
2 Missing values for: duration on ART, n=11 cases, n=0 controls; attending school currently, n=5 cases, n=0 
controls; Repeated ≥1 school grade, n=9 cases, n=1 controls; taking cotrimoxazole prophylaxis, n=2 cases, 
n=3 controls; ART regimen, n=1 cases, n=1 controls; past history of TB, n=0 cases, n=1 controls;
3 Only asked for those currently attending school. Missing values for: Same age as most children in the 
class, n=61 cases, n=9 controls
4 Only asked if past history of TB
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Table 2: Characteristics associated with chronic lung disease i.e. FEV 1 z-score <-1, complete case analysis n=323 cases and n=70 controls 
Characteristic Level N (%) with 
CLD 
Crude Odds ratio P-value Minimally 
adjusted Odds 
Ratio1  













0.99 (0.52, 1.89) 
0.99 1.0 (ref) 




































3.92 (1.73, 8.87) 
 
0.001 
















1.03 (0.50, 2.12) 
 
0.93 









5.82 (1.75, 19.32) 
















1.43 (0.76, 2.67) 
 
0.27 
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<200  34 (85.0%) 1.25 (0.51, 3.11) 0.62 1.41 (0.56, 3.57) 0.46 0.87 (0.30, 2.48) 











3.01 (1.43, 6.36) 
0.004 1.0 (ref) 









2.90 (1.34, 6.31) 
 
0.007 









1 Adjusted for age (6-9 years; 10-12 years; 13-16 years; 17-19 years) and duration of ARV treatment (6 months-2 years; 2-4 years; 4-6 years, more than 6 
years) 
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Figure 2. FEV1 distribution
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